Top Markets
#1 Islamic Coin Islamic Coin +154.42%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +21.40%
#4 BOOK OF MEME BOOK OF MEME +20.75%
#5 Starpower Starpower +13.95%
#6 Lighter Lighter +12.64%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.14%
#8 Nockchain Nockchain +11.13%
#9 SkyAI SkyAI +10.48%
#10 Meteora Meteora +10.46%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Kedudukan dalam Saham #28047
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Harga Saham
$0.55
Disegerakkan terakhir: 2025-02-11
Modal Pasaran
$28.90M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Marinus Pharmaceuticals, Inc. (MRNS)

Kategori

Healthcare
Pendapatan untuk Marinus Pharmaceuticals, Inc. (MRNS)
Pendapatan pada Sep 2024 TTM: $-140.49M
Menurut laporan kewangan terkini Marinus Pharmaceuticals, Inc., pendapatan semasa syarikat ialah $-140.49M. Pada tahun 2022, syarikat memperoleh pendapatan sebanyak $-16.43M, peningkatan berbanding pendapatan pada tahun 2021 yang berjumlah $-98.78M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Marinus Pharmaceuticals, Inc. dari 2012 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-140.49M -1.72%
2023 $-142.94M 770.17%
2022 $-16.43M -83.37%
2021 $-98.78M 46.39%
2020 $-67.48M 24.67%
2019 $-54.12M 47.36%
2018 $-36.73M 94.34%
2017 $-18.90M -34.02%
2016 $-28.64M 15.26%
2015 $-24.85M 129.39%
2014 $-10.83M 105.57%
2013 $-5.27M 274.13%
2012 $-1.41M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -3,854.62%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 2,097.29%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -1,488.45%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -1,249.03%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH